Published in Oncotarget on August 16, 2016
Cancer statistics, 2016. CA Cancer J Clin (2016) 32.95
Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell (1999) 32.32
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell (2004) 8.06
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res (2014) 7.15
Radical causes of cancer. Nat Rev Cancer (2003) 5.45
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res (2007) 4.95
The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol (2002) 4.85
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A (1995) 3.28
MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg (2008) 2.86
Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol (2004) 2.62
Tumour maintenance is mediated by eNOS. Nature (2008) 2.52
CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med (2015) 2.05
Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal (2010) 1.94
Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A (2004) 1.87
Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer. Exp Gerontol (2006) 1.77
Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Gastroenterology (2014) 1.71
Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer. Gastroenterology (2013) 1.67
Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res (2013) 1.67
Nitric oxide as a bioregulator of apoptosis. Biochem Biophys Res Commun (2001) 1.57
Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/AKT/FOXO pathway. Clin Cancer Res (2011) 1.42
Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer (2007) 1.38
The role of nitric oxide (NO.) in the carcinogenic process. Biochim Biophys Acta (1996) 1.30
Nitric oxide is a key component in inflammation-accelerated tumorigenesis. Cancer Res (2008) 1.19
S-nitrosylation at cysteine 498 of c-Src tyrosine kinase regulates nitric oxide-mediated cell invasion. J Biol Chem (2009) 1.17
Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene (2013) 1.17
Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res (2004) 1.15
Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A (2009) 1.15
Association of increased immunostaining for inducible nitric oxide synthase and nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer. Arch Surg (1999) 1.12
Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP. Cell Cycle (2010) 1.04
Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Int J Cancer (2013) 0.99
Nitric oxide production in relation to spontaneous B-cell lymphoma and myositis in SJL mice. Cancer Res (1995) 0.95
Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol (2002) 0.95
NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression. Int J Cancer (2012) 0.95
Targeting eNOS in pancreatic cancer. Cancer Res (2012) 0.94
Nitric oxide inhibits the proliferation and invasion of pancreatic cancer cells through degradation of insulin receptor substrate-1 protein. Mol Cancer Res (2010) 0.83
LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. J Clin Invest (2015) 0.82
A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. Int J Pancreatol (2001) 0.79
Interplay of miR-21 and FoxO1 modulates growth of pancreatic ductal adenocarcinoma. Tumour Biol (2015) 0.79